Fasudil prevents KATP channel-induced improvement in postischemic functional recovery

Kenya Nishizawa1, Paul E Wolkowicz, Tadashi Yamagishi

  • 1Dept. of Medicine, Univ. of Alabama at Birmingham, Birmingham, AL 35294, USA.

Insights

Activation of ATP-dependent potassium (K(ATP)) channels improves heart recovery after ischemia. Rho kinase (ROCK) activity is crucial for this K(ATP) channel-induced cardioprotection, as inhibiting ROCK blocks the beneficial effects.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Cell Signaling

Background:

  • ATP-dependent potassium (K(ATP)) channels are known to enhance myocardial recovery post-ischemia.
  • The precise molecular mechanisms underlying K(ATP) channel-mediated cardioprotection are not fully understood.
  • RhoA, a GTPase, influences cellular processes relevant to K(ATP) channel function.

Purpose of the Study:

  • To investigate whether rho kinase (ROCK), a key effector of RhoA, is essential for K(ATP) channel-induced cardioprotection.
  • To elucidate the role of ROCK in the beneficial effects of K(ATP) channel activation on the ischemic heart.

Main Methods:

  • Utilized isolated perfused rat hearts subjected to a model of ischemia-reperfusion.
  • Compared mechanical function and high-energy phosphate levels ((31)P NMR) across four experimental groups: untreated, K(ATP) channel activation (pinacidil), ROCK inhibition (fasudil), and combined treatment.
  • Administered pinacidil to activate K(ATP) channels and fasudil to inhibit ROCK.

Main Results:

  • Pinacidil treatment significantly improved post-ischemic mechanical recovery, indicated by increased left ventricular diastolic pressure (LVDP).
  • Fasudil alone did not alter reperfusion LVDP but completely abolished the protective effects of pinacidil.
  • ROCK inhibition also led to substantial attenuation of post-ischemic energetic recovery.

Conclusions:

  • Rho kinase (ROCK) activity is a necessary component for K(ATP) channel-induced cardioprotection.
  • These findings support the hypothesis that ROCK signaling plays a critical role in mediating the beneficial effects of K(ATP) channel activation on the heart during and after ischemia.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...